QIAGEN GmbH appears in FDA device records as the applicant behind the QIAstat-Dx BCID GN Plus AMR Panel, cleared under K262168 with a substantially equivalent decision dated September 24, 2026. The filing lists a Hilden, Germany address and assigns the device to microbiology under product code PEN. The panel is one entry in a broader QIAstat-Dx bloodstream infection menu that QIAGEN describes in its own materials, and the company's published documentation covers both the U.S. clearance and a CE-marked instructions-for-use revision. [1][3][4][5]
The cleared panel and its filing record
The FDA 510(k) record for K262168 identifies the device as the QIAstat-Dx BCID GN Plus AMR Panel, with the openFDA device name given as gram-negative bacteria and associated resistance markers. The application was received June 26, 2026, reviewed under the microbiology advisory committee, and decided September 24, 2026 as substantially equivalent under a traditional clearance with a summary statement. The regulation number is 866.3365 and the device class is 2. [1]
QIAGEN's own announcement frames the clearance as completing its U.S. QIAstat-Dx bloodstream infection portfolio, and states that the test identifies 13 gram-negative bacterial targets and 18 antibiotic resistance markers in about one hour. Those target counts and the turnaround figure are the manufacturer's characterization, not values taken from the FDA decision record. [5]
Documented components and intended instrument
The Summary of Safety and Performance for the panel is dated September 2026 and states in vitro diagnostic use with the QIAstat-Dx Analyzer 1.0 and QIAstat-Dx Analyzer 2.0. It carries QIAGEN GmbH's Hilden address and a notified body number, and its revision page records validation by the Notified Body on September 1, 2026, with English as the validation language. [3]
The Instructions for Use, Rev. 01 dated August 2026, repeats the in vitro diagnostic designation and the same two analyzer versions, and includes a results-interpretation section covering internal control and sample result interpretation. The document's trademark notice names QIAGEN, Sample to Insight and QIAstat-Dx as QIAGEN Group marks. [4]
Adjacent filings and the gram-positive counterpart
A separate FDA record, K254194/S001, addresses the QIAstat-Dx BCID GPF Plus AMR Panel under the same regulation, 21 CFR 866.3365, described as a multiplex nucleic acid assay for identification of microorganisms and resistance markers from positive blood cultures, in Class II with product codes PAM and PEO. The letter is addressed to QIAGEN GmbH care of a regulatory affairs contact at a Germantown, Maryland address, and names ePlex Blood Culture Identification Gram Positive and Fungal Pathogen panels as predicate devices. [9]
QIAGEN's BCID page describes blood culture identification as combining pathogen and antimicrobial resistance detection, with rapid molecular methods complementing conventional microbiology workflows. The page states that the QIAstat-Dx BCID Plus AMR Panels are intended for in vitro diagnostic use. [6]
What the filing record does and does not establish
The linked collection for this applicant contains one 510(k) record, and that single record carries a substantially equivalent decision. This is a count of the filings assembled as of the snapshot date, not a measure of company sales, total product portfolio or safety performance, and it should not be read as a clearance rate. [1]
A registered clinical performance study for the QIAstat-Dx BCID Plus AMR Panels appears on ClinicalTrials.gov under identifier NCT05305534. The record's listed contents in the available material do not extend to enrollment, endpoints or results, so the study's findings remain unknown here. QIAGEN's U.S. QIAstat-Dx product page describes multiplex syndromic testing applications without adding panel-level performance data. [7][8]
